Single versus sequential high-dose chemotherapy (HOCT) in patients with relapsed or refractory germ-cell tumors (GCT).

被引：0
|
作者：
Lorch, A.
Rick, O.
Hartmann, J. T.
Kollmannsberger, C.
Metzner, B.
Schmidt-Wolf, I.
Berdel, W. E.
Schirren, R.
Beyer, J.
Bokemeyer, C.
机构：
[1] Univ Hosp, Marburg, Germany
[2] Klin Reinhardshoehe, Bad Wildungen, Germany
[3] Univ Hosp, Tubingen, Germany
[4] BC Canc Agcy, Vancouver, BC, Canada
[5] Staedt Kliniken, Oldenburg, Germany
[6] Univ Hosp Bonn, Bonn, Germany
[7] Univ Hosp, Munster, Germany
[8] Oberschwabenklin, Ravensburg, Germany
[9] Univ Hosp, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：219S / 219S
页数：1
相关论文
共 50 条
  • [31] Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
    Nieto, Yago
    Tu, Shi-Ming
    Jones, Roy B.
    Tannir, Nizar M.
    Bassett, Roland L.
    Margolin, Kim Allyson
    Holmberg, Leona
    Champlin, Richard E.
    Pagliaro, Lance C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Comparison of three or fewer sequential high-dose chemotherapy cycles as salvage treatment in germ-cell tumors
    Goessi, F.
    Spahn, M.
    Zweifel, M.
    Schardt, J.
    Thalmann, G.
    Pabst, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 20 - 20
  • [33] Evaluation of prognosis in relapsed germ cell tumors: Identification of patients who profit from high dose chemotherapy (HOCT).
    Sammler, C.
    Beyer, J.
    Bokemeyer, C.
    Hartmann, J.
    Siegert, W.
    Rick, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 237S - 237S
  • [34] Infusional gemcitabine plus docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
    Nieto, Yago
    Tu, Shi-Ming
    Campbell, Matthew T.
    Bassett, Roland
    Tannir, Nizar M.
    Ward, John Francis
    Hofstetter, Wayne Lewis
    Jones, Roy B.
    Andersson, Borje
    Gulbis, Alison M.
    Ledesma, Celina
    Timmons, Melissa
    Trapp, Michelle
    Champlin, Richard E.
    Pagliaro, Lance C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] High-dose chemotherapy with autologous peripheral blood progenitor cell transplantetion in patients with germ-cell tumors
    Nepomucká, J
    Boublikoviá, L
    Donátová Z, Z
    Charvát, J
    Kalanin, J
    Greplová, M
    Bártová, M
    Abrahámová, J
    BONE MARROW TRANSPLANTATION, 2002, 29 : S189 - S190
  • [36] The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors
    Oing, Christoph
    Lorch, Anja
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (06) : 365 - 369
  • [37] High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors
    Einhorn, Lawrence H.
    Williams, Stephen D.
    Chamness, Amy
    Brames, Mary J.
    Perkins, Susan M.
    Abonour, Rafat
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (04): : 340 - 348
  • [38] Outcome in 41 patients with late relapse germ cell tumors (GCT) treated with high-dose chemotherapy (HDCT)
    Lorch, A.
    Rick, O.
    Hartmann, J. T.
    Metzner, B.
    Glasmacher, A.
    Berdel, W.
    Schirren, R.
    Bokemeyer, C.
    Beyer, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Prognostic factors for high-dose chemotherapy (HDCT) as salvage treatment in germ cell tumors (GCT)
    Beyer, J
    Kramar, A
    Mandanas, R
    Linkesch, W
    Greinix, A
    Droz, JP
    Pico, JL
    Diehl, A
    Bokemeyer, C
    Schmoll, HJ
    Nichols, CR
    Einhorn, LH
    Siegert, W
    BONE MARROW TRANSPLANTATION, 1998, 22 : S10 - S10
  • [40] High-dose chemotherapy (HDCT) plus peripheral-blood stem-cell transplant (PBSCT) for patients (pts) with relapsed germ-cell tumors (GCT) and active brain metastases (mets).
    Kalra, Maitri
    Adra, Nabil
    Mckay, John
    Abonour, Rafat
    Hanna, Nasser H.
    Einhorn, Lawrence H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345